SPHS News Alert Sophiris Bio Inc (SPHS) 2.82 12/13/2014 07:3

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sophiris Bio Inc (SPHS) 2.82 $SPHS

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 11:46AM CST

ANV: 0.74 (-0.04), FRO: 2.25 (+0.62), EXXI: 2.84 (unch), SPRO: 1.72 (+0.01), EMES: 44.67 (+0.92), BDR: 2.28 (-0.02), SPHS: 2.82 (+0.03), ISR: 1.62 (-0.02), MILL: 1.24 (unch), EOX: 0.97 (-0.31), NADL: 1.47 (-0.09), ORPN: 6.71 (-0.54), CANF: 3.49 (+0.03), LAS: 0.98 (-0.09), MOLG: 2.90 (-0.05), PSIX: 44.36 (-1.35), GDP: 3.93 (-0.33), LRE: 7.47 (-0.06), NGD: 4.35 (+0.04), BDL: 32.60 (+0.30)

Sophiris Bio to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Tue Nov 25, 7:00AM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized low to intermediate risk prostate cancer, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 26th Annual Piper Jaffray Healthcare Conference. The presentation is scheduled for Tuesday, December 2, 2014 at 12:50 p.m. EST in New York City.
SPHS: 2.82 (+0.03)

Sophiris Bio - Upcoming Catalysts Present Very Attractive Upside
Daniel Ward - at Seeking Alpha - Mon Nov 24, 8:30AM CST

SPHS: 2.82 (+0.03)

Sophiris Bio beats by $0.03
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:55PM CST

SPHS: 2.82 (+0.03)

Sophiris Bio Reports Third Quarter Financial Results
Business Wire - Wed Nov 12, 3:05PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized low to intermediate risk prostate cancer, today announced financial results for the three and nine months ended September 30, 2014.
SPHS: 2.82 (+0.03)

Sophiris Bio to Present at the Stifel 2014 Healthcare Conference
Business Wire - Fri Nov 07, 3:05PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized low to intermediate risk prostate cancer, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Stifel 2014 Healthcare Conference. The presentation is scheduled for Tuesday, November 18, 2014 at 3:35 pm EST in New York City.
SPHS: 2.82 (+0.03)

Strength Seen in Sophiris Bio (SPHS): Stock Soars 25% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:46AM CST
Sophiris Bio (SPHS) was a big mover last session, as the company saw its shares surge 25% on the day.
ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), GWPH: 72.41 (+1.18), SPHS: 2.82 (+0.03)

3 Under-$10 Health Care Stocks Triggering Breakout Trades
at The Street - Fri Oct 10, 8:08AM CDT
Keep these health care stocks under $10 on your breakout trading radar.
SPHS: 2.82 (+0.03), PIP: 1.72 (+0.01), MEIP: 4.20 (unch)

Sophiris Bio to Present at the 13th Annual BIO Investor Forum
Business Wire - Tue Sep 30, 7:01AM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized prostate cancer, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 13th Annual BIO Investor Forum. The presentation is scheduled for Tuesday, October 7, 2014 at 8:00 a.m. PDT in San Francisco.
SPHS: 2.82 (+0.03)

Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
Business Wire - Tue Sep 02, 7:00AM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized prostate cancer, today announced that it has fully enrolled its ongoing Phase 3 trial (referred to as PLUS-1) of PRX302 as a treatment for lower urinary tract symptoms of BPH.
SPHS: 2.82 (+0.03)

Sophiris Bio Reports Second Quarter Financial Results and Key Operational and Financial Highlights
Business Wire - Thu Aug 07, 3:06PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized prostate cancer, today announced financial results and recent key operational and financial highlights for the three and six months ended June 30, 2014.
SPHS: 2.82 (+0.03)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 129

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 146

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading
New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 139

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 103

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 254

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 66

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 35

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 50

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading

Top 5 Most Recently Viewed Articles

Citi Raises Price Target for Blackstone Amid Encouraging Outlook

Updated Category News Views 131

Citi's Updated Outlook on Blackstone Recently, Citi revisited its financial forecast for The Blackstone Group (NYSE: BX), adjusting the price target upward from $157.00 to $170.00 while maintaining a Neutral stance on the stock. This update follows the company's impressive third-quarter performance, which saw Blackstone's stock rise by 6.3% post-earnings announcement....

Continue Reading
JAB's Strategic Acquisition of Mondelez Shares in JDE Peet's

Updated Category News Views 92

JAB's Significant Move in the Coffee Industry In a strategic and noteworthy development, JAB has made headlines by agreeing to acquire a substantial share package from Mondelez, focusing on Dutch coffee giant JDE Peet's. This major transaction amounts to approximately €2.2 billion, or about $2.4 billion. JAB intends to purchase 86 million shares at a price of €25.10...

Continue Reading
Urgent Update for DXC Technology Company Investors

Updated Category News Views 272

DXC Technology Company (NYSE: DXC) found itself in hot water back in 2024 when shareholders raised hell over alleged falsehoods that inflated stock prices. The Rosen Law Firm rolled out a class action lawsuit aimed at those who bought shares during what they dubbed the Class Period—a time rife with questionable operational claims from DXC's brass. Allegations Surface:...

Continue Reading
Investigation Launched: National Grid Faces Legal Scrutiny

Updated Category News Views 283

Bragar Eagel & Squire, P.C. Initiates Investigation Bragar Eagel & Squire, P.C., a well-regarded law firm known for advocating for investors, has begun an investigation surrounding concerns related to National Grid plc (NYSE: NGG). This inquiry primarily aims to assist stockholders who may have experienced losses while owning shares of National Grid. The firm invites...

Continue Reading
Oil & Gas Sector Trends: Path to 8.79 Trillion Growth

Updated Category News Views 223

Oil & Gas Market Growth and Projections The global oil and gas market has positioned itself for remarkable expansion. With estimates currently valuing the market at approximately USD 6.10 trillion, projections suggest it could soar to around USD 8.79 trillion by 2034. This growth translates to a compound annual growth rate (CAGR) of 3.72% between 2025 and 2034. Notably,...

Continue Reading